The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL
Salim Yazji, MD, Oncternal Therapeutics, San Diego, CA, comments on the rationale and design of ZILO-301, a Phase III study comparing the safety and efficacy of zilovertamab plus ibrutinib vs ibrutinib alone in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) (NCT05431179). Dr Yazji also briefly talks on a ROR1-directed CAR-T therapy that is currently being developed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Oncternal Therapeutics
